A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer.
Marcel Philipp TrefnySacha I RothschildFranziska UhlenbrockDietmar RiederBenjamin KasendaMichal A StanczakFiamma BernerAbhishek S KashyapMonika KaiserPetra HerzigSeverin PoechtragerDaniela S ThommenFlorian GeierSpasenija SavicPhilip JermannIlaria AlborelliStefan SchaubFrank StennerMartin FrühZlatko TrajanoskiLukas FlatzKirsten D MertzAlfred ZippeliusHeinz LaubliPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
We identified an association of the KIR3DS1 allelic variant with response to PD-1-targeted immunotherapy in patients with NSCLC. This finding links NK cells with response to PD-1 therapy. Although the findings are interesting, a larger analysis in a randomized trial will be needed to confirm KIRs as predictive markers for response to PD-1-targeted immunotherapy.